Abstract
Since 2022, Europe has had 4 cases of extensively drug-resistant Neisseria gonorrhoeae, sequence type 16406, that is resistant to ceftriaxone and highly resistant to azithromycin. We report 2 new cases from France in 2023 involving strains genetically related to the 4 cases from Europe as well as isolates from Cambodia.
Keywords:
A2059G mutation; Azithromycin; Ceftriaxone; Drug-resistant; France; Neisseria gonorrhoeae; ST16406; antimicrobial resistance; bacteria; gonorrhea; penA-60.001; sexually transmitted infections; surveillance.
MeSH terms
-
Adult
-
Anti-Bacterial Agents* / pharmacology
-
Anti-Bacterial Agents* / therapeutic use
-
Azithromycin / pharmacology
-
Azithromycin / therapeutic use
-
Ceftriaxone / pharmacology
-
Ceftriaxone / therapeutic use
-
Drug Resistance, Multiple, Bacterial* / genetics
-
Female
-
France / epidemiology
-
Gonorrhea* / drug therapy
-
Gonorrhea* / epidemiology
-
Gonorrhea* / microbiology
-
Humans
-
Male
-
Microbial Sensitivity Tests
-
Neisseria gonorrhoeae* / drug effects
-
Neisseria gonorrhoeae* / genetics
-
Neisseria gonorrhoeae* / isolation & purification
Substances
-
Anti-Bacterial Agents
-
Azithromycin
-
Ceftriaxone